


IMPORTANT NOTICE: IF YOUR FINANCIAL ADVISOR RECOMMENDED ESSA PHARMA INVESTMENTS PLEASE CONTACT KT LAW

KlaymanToskes Investigates on Behalf of Investors Who Were Recommended ESSA Pharma, Inc. Investments By Their Broker/Advisor

NEW YORK, NY, UNITED STATES, February 4, 2025 /EINPresswire.com/ -- National investment loss and securities lawyers [KlaymanToskes](#) issues an important notice to investors who suffered significant losses in ESSA Pharma, Inc. (NASDAQ: EPIX). The law firm urges customers of brokerage firms and financial advisors who suffered investment losses in excess of \$100,000 in ESSA Pharma, Inc. to contact the firm immediately at 888-997-9956. Investors with self-directed accounts who did not rely on the advice of a financial advisor are not eligible for our representation.



KlaymanToskes is investigating brokerage firms and financial advisors that recommended investments in ESSA Pharma, Inc. to their customers. On October 31, 2024, ESSA Pharma announced the termination of its Phase 2 M-E Combination Study, and disclosed that it planned to terminate all other company-sponsored and investigator-sponsored clinical studies involving masofaniten. Following this announcement, ESSA's stock price plummeted by 73.08%, dropping from \$5.20 per share to \$1.40 per share on November 1, 2024.

Our investigation has led the law firm to believe that investment firms and their financial advisors may have failed to act in the best interest of their customers, and misrepresented the risk-factors related to investments in ESSA Pharma, in addition to failing to conduct due diligence on ESSA Pharma's investment offering, leading to unsuitable recommendations.

Financial advisors and their firms may be held liable for any losses incurred by their customers in the event of failure to act in the best interest of the customer, unsuitable investment recommendations, misrepresentations or omissions of material facts, and/or an overconcentration of the customer's portfolio in one particular investment, class, or market sector. Further, financial professionals and their firms cannot disregard a customer's risk-tolerance when making investment recommendations.

Depending on your circumstances, you may be entitled to recover your losses through [FINRA arbitration](#), which may result in a greater and additional recovery to solely participating and waiting for any recovery in any class action lawsuit.

Investors who suffered losses over \$100,000 in ESSA Pharma, Inc. are encouraged to contact attorney [Steven D. Toskes](#) at (888) 997-9956 or by email at investigations@klaymantoskes.com in furtherance of our investigation. Investors with self-directed accounts who did not rely on the advice of a financial advisor are not eligible for our representation.

About KlaymanToskes

KlaymanToskes is a leading national securities law firm which practices exclusively in the field of securities arbitration and litigation on behalf of retail and institutional investors throughout the world in large and complex securities matters. The firm has recovered over \$250 million in FINRA arbitrations and over \$350 million in other securities litigation matters. KlaymanToskes has office locations in California, Florida, New York, and Puerto Rico.

Contact

Steven D. Toskes, Esq.
KlaymanToskes, P.A.
+1 888-997-9956
investigations@klaymantoskes.com

This press release can be viewed online at: <https://www.einpresswire.com/article/782915481>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.